scholarly journals A COMPARISON OF INTRACORONARY BRACHYTHERAPY IN THE DRUG-ELUTING VERSUS BARE METAL STENT ERA

2018 ◽  
Vol 71 (11) ◽  
pp. A1366
Author(s):  
John Wagener ◽  
Michael Johnson ◽  
Amr Essa ◽  
Jay Ciezki ◽  
Sheen Cherian ◽  
...  
2021 ◽  
Vol 32 (5) ◽  
pp. S6-S7
Author(s):  
O. Adenikinju ◽  
S. Vianna ◽  
D. Rubin ◽  
F. Ujueta ◽  
B. Money ◽  
...  

2016 ◽  
Vol 31 (6) ◽  
pp. 911-922 ◽  
Author(s):  
Xiangshan Xu ◽  
Lijie Wang ◽  
Guofeng Wang ◽  
Yuanzhe Jin

The coronary artery stent has been widely used in clinic. In-stent restenosis was mainly caused by the excessive proliferation of smooth muscle cell and the inflammation due to the metal ion released from stent scaffold of the drug-eluting stent. Thus, to reduce the in-stent restenosis and promote the vascular endothelialization have become a hot research point in this area. In this paper, a nano-TiO2 ceramic coating was deposited on 316L stainless steel to reduce the metal ion release and to inhibit the inflammation reaction. An endothelia cell selective adhesion peptide Arg-Glu-Asp-Val (REDV) coating was prepared on the ceramic coating by a polydopamine technology to promote the endothelialization. The corrosion test indicated that nano-TiO2 ceramic film could effectively decrease the nickel ion released from 316L stainless steel. REDV/TiO2 coating could promote the endothelial cell adhesion and proliferation, meanwhile REDV/TiO2 coating could also increase the nitric oxide concentration. Bare metal stent, TiO2-coated stent and REDV/TiO2-coated stent were implanted in the iliac arteries of rabbit model. In-stent restenosis and re-endothelialization were evaluated at 28 days post-implantation of the stents. The results showed that REDV/TiO2-coated stents could effectively reduce in-stent restenosis and promote re-endothelialization in comparison with TiO2-coated drug-eluting stent and bare metal stent. These results suggest that REDV/TiO2-coated drug-eluting stent maybe a good choice of the application for coronary artery disease.


2011 ◽  
Vol 75 (2) ◽  
pp. 290-298 ◽  
Author(s):  
Shu-Kai Hsueh ◽  
Chiung-Jen Wu ◽  
Hsiu-Yu Fang ◽  
Yuan-Kai Hsieh ◽  
Chih-Yuan Fang ◽  
...  

2010 ◽  
Vol 210 (2) ◽  
pp. 503-509 ◽  
Author(s):  
Johann Auer ◽  
Alexander Leitner ◽  
Robert Berent ◽  
Gudrun Lamm ◽  
Elisabeth Lassnig ◽  
...  

2006 ◽  
Vol 134 (3-4) ◽  
pp. 155-158 ◽  
Author(s):  
Svetlana Apostolovic ◽  
Zoran Perisic ◽  
Miloje Tomasevic ◽  
Goran Stankovic ◽  
Milan Pavlovic ◽  
...  

Stent thrombosis remains the primary cause of death after percutaneous coronary interventions (PCI). Despite modern concepts of PCI, stent thrombosis occurs in 0.5% -2% of elective procedures and even 6% of patients with the acute coronary syndrome (ACS). Stent thrombosis most often develops within the first 48 hours after the PCI, and rarely after a week of stent implantation. Angiographically documented late (>6 months) thrombosis of coronary bare-metal stent (BMS) is rare, because the stent endothelialization is considered to be completed after four weeks of the intervention. Our patient is a 41 year old male and he had BMS thrombosis 345 days after the implantation, which was clinically manifested as an acute myocardial infarction in the inferoposterolateral localization. Stent Clinical Centre of Serbia, Belgrade thrombosis occurred despite a long term dual antiplatelet therapy and control of known risk factors. Thrombolytic therapy (Streptokinase in a dose of 1 500 000 IU) was not successful in reopening the occluded vessel, so the flow through the coronary artery was achieved by rescue balloon angioplasty, followed by implantation of drug eluting stent in order to prevent restenosis.


Sign in / Sign up

Export Citation Format

Share Document